Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Central Nervous System Infections in Denmark

Lead Sponsor:

Aalborg University Hospital

Collaborating Sponsors:

Danish Study Group of Infections of the Brain

Conditions:

Central Nervous System Infections

Bacterial Meningitis

Eligibility:

All Genders

18+ years

Brief Summary

The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervo...

Detailed Description

The investigators include data on diagnosis at admission, symptoms and signs on admission, character and timing of diagnostic work-up and treatment and outcome assessed by the Glasgow Outcome Score (G...

Eligibility Criteria

Inclusion

  • Definitions of central nervous system infections:
  • For all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.
  • Viral meningitis inclusion criteria
  • \- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)
  • and
  • Cerebrospinal fluid leukocytes\>10 cells/ml
  • Patients with viral meningitis with undetermined pathogen have to have:
  • CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
  • In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.
  • Bacterial meningitis inclusion criteria - All patients have to have a clinical presentation consistent with bacterial meningitis (e.g. headache, neck stiffness, fever, altered mental status)
  • and
  • Proven bacterial aetiology (CSF or blood culture/DNA based technology or antigen tests)
  • Patients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:
  • \- CSF leukocytes\> 10/mL and no other more probable diagnosis assessed by the local investigator.
  • In case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.
  • Encephalitis inclusion criteria - All patients have to have a clinical presentation consistent with encephalitis (e.g. headache, fever, focal neurological deficit, altered mental status \>24 hours) as defined by the International Encephalitis Consortium (Venkatesan A et al., Clin Infect Dis 2013; doi:10.1093/cid/cit458.).
  • Encephalitis exclusion criteria
  • \- We exclude cases of proven or suspected autoimmune encephalitis.
  • Primary brain abscess inclusion criteria
  • \- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)
  • and
  • \- Proven microbiological aetiology by culture/DNA-based technology from pus from brain abscess or blood or CSF
  • or
  • \- Aspiration of pus from the brain abscess
  • or
  • \- Response to antimicrobial treatment
  • or
  • \- Tumour ruled out
  • or
  • \- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.
  • Lyme neuroborreliosis inclusion criteria
  • \- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)
  • and
  • \- CSF pleocytosis\>10 leukocytes/mL
  • and
  • \- Positive intrathecal B.burgdorferi antibody production index.
  • Neurosyphilis inclusion criteria - A clinical presentation consistent with neurosyphilis (e.g. 'encephalitis-like symptoms', dementia, ocular or otogenic syphilis)
  • and either
  • \- Positive syphilis serology in serum combined with CSF leukocytes\>10/mL
  • or
  • \- CSF syphilis antibodies.

Exclusion

    Key Trial Info

    Start Date :

    January 1 2015

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    January 1 2030

    Estimated Enrollment :

    1900 Patients enrolled

    Trial Details

    Trial ID

    NCT03418441

    Start Date

    January 1 2015

    End Date

    January 1 2030

    Last Update

    May 16 2024

    Active Locations (8)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (8 locations)

    1

    Department of Infectious Diseases, Aalborg University Hospital

    Aalborg, Denmark, 9000

    2

    Department of Infectious Diseases, Aarhus University Hospital Skejby

    Aarhus, Denmark, 8000

    3

    Department of Infectious Diseases, Rigshospitalet

    Copenhagen, Denmark, 2100

    4

    Herlev-Gentofte Hospital

    Copenhagen, Denmark